Search clinical trials for: KY1044 and atezolizumab

Total 270329 results

Hoffmann-La Roche

Completed

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

Melanoma

United States, Italy, Australia, France, Spain, Netherlands
Centre Hospitalier Universitaire de Besancon
Roche Pharma AG; National Cancer Institute, France

Active, not recruiting

Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL) (VolATIL)

Cervical Cancer | Squamous Cell Carcinoma of the Head and Neck | Anal Canal Cancer

France
Fox Chase Cancer Center
Genentech, Inc.

Active, not recruiting

Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer

HER2-positive Breast Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Squamous Cell Carcinoma of the Head and Neck

France, United States, Israel, Korea, Republic of, Australia
Mario Negri Institute for Pharmacological Research
Hoffmann-La Roche

Active, not recruiting

Atezolizumab Trial in Endometrial Cancer - AtTEnd (AtTEnd)

Endometrial Cancer

New Zealand, Korea, Republic of, United Kingdom, Italy, Spain, Japan, Germany, Australia, Switzerland, Austria, Taiwan
Syndax Pharmaceuticals
Roche Pharma AG

Completed

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Breast Cancer

United States, Georgia
G1 Therapeutics, Inc.
Roche-Genentech

Terminated

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

Small Cell Lung Cancer

United States, Spain, France, Bulgaria, Ukraine, Estonia, Latvia
M.D. Anderson Cancer Center

Completed

Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma

United States
Medical University of South Carolina

Completed

LIVE-C-Free: Early and Late Treatment of Hepatitis C With Sofosbuvir/Ledipasvir in Liver Transplant Recipients

Hepatitis C

United States
European Organisation for Research and Treatment...

Completed

Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

Ovarian Neoplasms

Spain, Switzerland, Netherlands, United Kingdom, France
University of Oklahoma
Genentech, Inc.

Recruiting

Phase II Study of Atezolizumab + Bevacizumab in Endometrial Cancer

Endometrial Cancer

United States
BioNTech SE

Active, not recruiting

Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411

Solid Tumor | Extensive-stage Small Cell Lung Cancer

United States, Spain, United Kingdom, Germany
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer (EL1SSAR)

Triple-Negative Breast Cancer

Italy, Portugal, Slovenia, Spain, Romania, France, Czechia, Peru, Argentina, Chile, Hungary, Mexico, Poland
Hoffmann-La Roche

Completed

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

Breast Cancer

France, United States, Spain, United Kingdom, Australia
University Hospital, Grenoble
NETRIS Pharma

Recruiting

Study Investigating the Association of NP137 With Atezolizumab-Bevacizumab Combination in First Line in Unresectable HCC (Liver-NET1)

Hepatocellular Carcinoma

France
Gustave Roussy, Cancer Campus, Grand Paris

Suspended

Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (ARIANES)

Solid Tumor

France
University Hospital, Grenoble
Genoscience Pharma

Recruiting

Ezurpimtrostat Autophagy Inhibitor in Association With Atezolizumab-Bevacizumab in First Line Treatment of Unresectable Hepatocellular Carcinoma (ABE-LIVER)

Hepatocellular Carcinoma

France
Exelixis

Active, not recruiting

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy (COSMIC-312)

Hepatocellular Carcinoma

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Colombia, Czechia, France, Georgia, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Korea, Republic of, Mexico, Netherlands, New Zealand, Philippines, ... and more
Queen Mary University of London
Hoffmann-La Roche; Polaris Group

Withdrawn

Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin (iTRAP)

Carcinoma, Non-Small-Cell Lung
American Society of Clinical Oncology
Bristol-Myers Squibb; Eli Lilly and Company; Bayer; Merck Sharp & Dohme LLC; Pfizer; AstraZene... and other collaborators

Recruiting

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Advanced Solid Tumors

United States
Tae Won Kim

Recruiting

DYNAmic Immune Microenvironment of HCC Treated With atezolIzumab Plus bevaCizumab (DYNAMIC)

Hepatocellular Carcinoma

Korea, Republic of
Centre Hospitalier Universitaire de Besancon
GERCOR - Multidisciplinary Oncology Cooperative Group; PRODIGE

Recruiting

Evaluation of the Interest to Combine a CD4 Th1-inducer Cancer Vaccine Derived From Telomerase and Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma (TERTIO)

Hepatocellular Carcinoma

France
Hoffmann-La Roche

Terminated

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Castration-Resistant Prostatic Cancer

Spain, France, Switzerland, Italy
Weill Medical College of Cornell University

Terminated

A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers

Metastatic Renal Cell Carcinoma | Metastatic Urothelial Carcinoma

United States
Bristol-Myers Squibb

Completed

Multiple Ascending Dose (MDX1105-01) (Anti-PDL1)

Cancer, Multiple Indications

United States
Georgetown University
Genentech, Inc.; Natera, Inc.

Recruiting

Evaluating Novel Therapies in ctDNA Positive GI Cancers (MRD-GI)

Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Gastric Adenocarcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | Gallbladder Adenocarcinoma | Adenocarcinoma of Biliary Tract

United States
Duke University

Terminated

Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib

Non Small Cell Lung Cancer

United States
University Health Network, Toronto

Withdrawn

Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer

Fallopian Tube Cancer | Primary Peritoneal Cancer | Ovarian Endometrioid Tumor | TP53 Mutation

Canada
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation (IMbrave050)

Carcinoma, Hepatocellular

United States, Korea, Republic of, Belgium, China, Japan, Brazil, Italy, Spain, Thailand, Australia, Costa Rica, Austria, France, Singapore, Taiwan, New Zealand, Canada, Germany, Hong Kong, Peru, Mexico, Netherlands, Czechia, Turkey, Po... and more
Columbia University
Genentech, Inc.

Active, not recruiting

Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies (MEKiAUTO)

Gastrointestinal Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab (Tecentriq) in Combination With Bevacizumab to Investigate Safety and Efficacy in Patients With Unresectable Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy-Amethista (AMETHISTA)

Carcinoma, Hepatocellular

Italy
Howard S Hochster
Genentech, Inc.; Rutgers Cancer Institute of New Jersey

Active, not recruiting

A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma (AB7)

Unresectable Hepatocellular Carcinoma

United States
Hoffmann-La Roche

Completed

Atezolizumab in Combination With Bevacizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma

Melanoma

China
M.D. Anderson Cancer Center
Helsinn Healthcare SA

Withdrawn

Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification

Cholangiocarcinoma | Liver Cancer

United States
AI Therapeutics, Inc.

Completed

A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (LAM-002A/NHL) (LAM-002A/NHL)

Lymphoma, Non-Hodgkin; Leukemia, Chronic Lymphocytic

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

Non-Small-Cell Lung

United States, Korea, Republic of, United Kingdom, Australia, France, Italy, Spain, Japan, Brazil, China, Germany, Poland, Thailand, Israel, Switzerland, Taiwan, Austria, Russian Federation, Ukraine, Hungary, Serbia, Slovenia, South... and more
Grupo Español de Investigación en Cáncer de Ovario
GlaxoSmithKline; Hoffmann-La Roche; Apices Soluciones S.L.; AGO Study Group; ARCAGY... and other collaborators

Active, not recruiting

Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA)

Recurrent Ovarian Carcinoma

France, Spain, Belgium, Italy, Germany
Chang Gung Memorial Hospital

Not yet recruiting

Atezolizumab and Bevacizumab With Photon Radiotherapy for Unresectable Hepatocellular Carcinoma (PhotonAB)

Hepatocellular Carcinoma

Taiwan
National Taiwan University Hospital

Recruiting

Immunotherapy With CCRT Followed by Surgery for Locally Advanced ESCC Patients

Locally Advanced Esophageal Squamous Cell Carcinoma

Taiwan
Massachusetts General Hospital
Genentech, Inc.

Recruiting

SBRT + Atezolizumab + Bevacizumab in Resectable HCC

Hepatocellular Carcinoma | Resectable Hepatocellular Carcinoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab With or Without Tiragolumab Following Neoadjuvant Chemoradiotherapy in Participants With Locally Advanced Rectal Cancer

Rectal Cancer | Rectal Neoplasms

China
Hoffmann-La Roche

Active, not recruiting

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

Carcinoma, Hepatocellular

Spain
Hoffmann-La Roche

Terminated

A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread

Breast Cancer

Israel, Italy, Spain, United States, Belgium, Czechia, Australia, United Kingdom, Korea, Republic of, Romania, France, Taiwan, Latvia
Inimmune Corporation
Avance Clinical Pty Ltd.

Not yet recruiting

Trial of INI-4001 in Patients With Advanced Solid Tumours

Advanced Solid Tumor

Australia
Genentech, Inc.

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors | Metastatic Solid Tumors

Canada, Korea, Republic of, United States, Brazil, Australia, Argentina, Spain, New Zealand, Poland
University Health Network, Toronto
Hoffmann-La Roche

Recruiting

An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)

Hepatocellular Carcinoma | Liver Metastases | Non-small Cell Lung Cancer Metastatic

Canada
Elizabeth Buchbinder, MD
Genentech, Inc.

Recruiting

A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

Stage IV Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Unresectable Stage III Cutaneous Melanoma | Unresectable Stage IV Cutaneous Melanoma

United States
Hoffmann-La Roche

Active, not recruiting

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Cancer

United States, Canada, France, Italy, Slovenia, Spain, Turkey, United Kingdom, Argentina, Brazil, Poland, Australia, Czechia, Thailand, Korea, Republic of, Russian Federation, Switzerland, Japan, Taiwan, Austria, Hungary, Belgium, P... and more
Centre Leon Berard

Active, not recruiting

Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck (ATHENA)

Head and Neck Neoplasms

France
Federation Francophone de Cancerologie Digestive

Recruiting

Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer (SIRTCI)

Metastatic Colorectal Cancer | MSS | pMMR | Immune Checkpoint Inhibitor | Internal Radiotherapy

France

Search clinical trials for: KY1044 and atezolizumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations